SCHEMBL29136007

SCHEMBL29136007

CNC(=O)c1cccc(Cn2cnc3cc(-c4cn[nH]c4C(F)(F)F)ccc3c2=O)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 2/20 0.48
ROCK2 O75116 1/20 0.48
GRK2 P25098 6/20 0.48
SLC2A1 P11166 4/20 0.46
GRK1 Q15835 1/20 0.45
TDO2 P48775 1/20 0.43
YTHDC1 Q96MU7 1/20 0.41
MAPK1 P28482 1/20 0.41
MMP13 P45452 1/20 0.40
METAP2 P50579 1/20 0.40
AURKA O14965 1/20 0.40
PRKCB P05771 1/20 0.40
AKT1 P31749 1/20 0.40
GRK5 P34947 1/20 0.40
GRK6 P43250 1/20 0.40
CAMK2B Q13554 1/20 0.40
RPS6KA1 Q15418 1/20 0.40
GRK7 Q8WTQ7 1/20 0.40
TNIK Q9UKE5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24617357 0.91 ROCK1 (0.48) ROCK1ROCK2GRK2SLC2A1GRK1
SCHEMBL24617396 0.90 GRK2 (0.47) ROCK1ROCK2GRK2SLC2A1GRK1
SCHEMBL24617501 0.90 GRK2 (0.46) ROCK1ROCK2GRK2SLC2A1GRK1
SCHEMBL24617318 0.90 GRK2 (0.41) ROCK1ROCK2GRK2SLC2A1GRK1
SCHEMBL24617326 0.89 GRK2 (0.42) ROCK1ROCK2GRK2SLC2A1GRK1
SCHEMBL29778992 0.88 MMP13 (0.46) ROCK1ROCK2GRK2SLC2A1GRK1
SCHEMBL24617397 0.88 MMP13 (0.46) ROCK1ROCK2GRK2SLC2A1GRK1
SCHEMBL29779089 0.88 ROCK1 (0.50) ROCK1ROCK2GRK2SLC2A1GRK1
SCHEMBL29135990 0.88 ROCK1 (0.50) ROCK1ROCK2GRK2SLC2A1GRK1
SCHEMBL24617399 0.87 KCNH2 (0.49) ROCK1ROCK2GRK2SLC2A1GRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 US claimed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 CN claimed
EP-4274825-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2023-11-15 EP claimed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 WO claimed
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 US disclosed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 CN disclosed
EP-4274825-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2023-11-15 EP disclosed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF ROCK2, ROCK1, MYLK3 ROCK1 2/4885ROCK2 1/4885GRK2 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.